Particles incorporating surfactants for pulmonary drug delivery

Patent Citations (31)

Non-Patent Literature (88)

• Hrkach et al., “Synthesis of Poly(L-lactic acid-co-L-Iysine) graft copolymers,” Macromolecules, 28:4736-4739, 1995.Applicant
• Hrkach et al., Poly(L-Lactic acid-co-amino acid) Graft Copolymers: A Class of Functional Biodegradable Biomaterials: in Hydrogels and Biodegradable Polymers for Bioapplications. ACS Symposium Series No. 627, Raphael M. Ottenbrite et al., Eds., American Chemical Society, Chapter 8, pp. 93-101, 1996.Applicant
• Adjei and Garren, “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers,” J. Pharm. Res., 7: 565-569 (1990).Applicant
• Altschuler et al., “Aerosol deposition in the human respiratory tract,” Am. Med. Assoc. Arch. Indust. Health 15:293-303 (1957).Applicant
• Anderson et al., “Effect of Cystic Fibrosis on Inhaled Aerosol Boluses,” Am. Rev. Respir. Dis., 140: 1317-1324 (1989).Applicant
• Barrera et al., “Synthesis and RGD Peptide Modification of a New Biodegradable Copolymer: Poly(lactic acid-co-lysine),” J. Am. Chem. Soc., 115:11010 (1993).Applicant
• Benita et al., “Characterization of drug-loaded poly(d,l-lactide) microspheres,” J. Pharm. Sci. 73, 1721-1724 (1984).Applicant
• Blackett and Buckton, “A Microcalorimetric Investigation of the Interaction of Surfactants with Crystalline and Partially Crystalline Salbutamol Sulphate in a Model Inhalation Aerosol System,” Pharmaceutical Research 12(11):1689-1693 (1995).Applicant
• **Brain, “Physiology and Pathophysiology of Pulmonary Macrophages,” in The Reticuloendothelial System, Reichard and Filkins, Eds., Plenum Press, New York, pp. 315-327 (1985).Applicant
• Byron, “Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung,” Adv. Drug. Del. Rev., 5: 107-132 (1990).Applicant
• Clark and Egan, “Modeling the deposition of inhaled powdered drug aerosols,” J. Aerosol Sci., 25:175-186 (1994).Applicant
• Clay et al., “Effect of aerosol particle size on bronchodilation with nebulized terbutaline in asthmatic subjects,” Thorax 41:364-368 (1986).Applicant
• Cohen et al., “Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres,” Pharm. Res., 8(6): 713-720 (1991).Applicant
• Colthorpe et al., “The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheals and Aerosol Administration to the Rabbit,” Pharm. Res. 9:764 (1992).Applicant
• Daly et al., “The Preparation of N-Carboxyanhydrides of α-Amino Acids Using Bis(Trichloromethyl)Carbonate,” Tetrahedron Lett., 29:5859 (1988).Applicant
• Damms and Bains, “The Cost of Delivering Drugs without Needles,”, J. Controlled Release, 8-11 (1996).Applicant
• Davies et al., “Breathing of half-micron aerosols. I. Experimental.,” J. Appl. Physiol. 32:591-600 (1972).Applicant
• Dorries and Valberg, “Heterogeneity of phagocytosis for inhaled versus instilled material,” Am. Rev. Resp. Disease, 146: 831-837 (1991).Applicant
• **Doubrow, Ed., “Microcapsules and Nanoparticles in Medicine and Pharmacy,” CRC Press, Boca Raton, 1992.Applicant
• Edwards, “The macrotransport of aerosol particles in the lung: Aerosol deposition phenomena,” J. Aerosol Sci., 26: 293-317 (1995).Applicant
• Eldridge et al., “Biodegradable microspheres as a vaccine delivery system,” Mol. Immunol., 28: 287-294 (1991).Applicant
• Findeisen, “Uber das Absetzen kleiner in der Luft suspendierter Teilchen in der menshilchen Lunge bei der Atmung,” Pflugers Arch. D. Ges. Physiol. 236:367-379 (1935).Applicant
• French, Edwards, and Niven, “The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation,” J. Aerosol Sci., 27: 769-783 (1996).Applicant
• Ganderton, “The generation of respirable clouds from coarse powder aggregates,” J. Pharmaceutical Sciences, 3:101-105 (1992).Applicant
• Gehr et al., “Surfactant and inhaled particles in the conducting airways: Structural, stereological, and biophysical aspects,” Microscopy Res. and Tech., 26: 423-436 (1993).Applicant
• Gerrity et al., “Calculated deposition of inhaled particles in the airway generations of normal subjects,” J. Appl. Phys., 47:867-873 (1979).Applicant
• Gonda, “Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract,” in Critical Reviews in Therapeutic Drug Carrier Systems 6:273-313 (1990).Applicant
• Gonda, “Preface. Major issues and future prospects in the delivery of therapeutic and diagnostic agents to the respiratory tract,” Adv. Drug Del. Rev., 5: 1-9 (1990).Applicant
• Gonda, “Physico-chemical principles in aerosol delivery,” in Topics in Pharmaceutical Sciences 1991, Crommelin, D.J, and K.K. Midha, Eds., Medpharm Scientific Publishers, Stuttgart, pp. 95-117, 1992.Applicant
• Gonda, “Targeting by Deposition,” in Pharmaceutical Inhalation Aerosol Technology (ed. A.J. Hickey), Marcel Dekkar Inc., New York, 1992.Applicant
• Heyder et al., “Mathematical model of particle deposition in the human respiratory tract,” J. Aerosol Sci., 17:811-825 (1986).Applicant
• Heyder and Rudolf, “Mathematical models of particle deposition in the human respiratory tract,” J. Aerosol Sci., 15:697-707 (1984).Applicant
• Heyder et al., “Total Deposition of Aerosol Particles in the Human Respiratory Tract for Nose and Mouth Breathing,” J. Aerosol Sci., 6:311-328 (1975).Applicant
• Hickey et al., “Use of particle morphology to influence the delivery of drugs from dry powder aerosols,” J. Biopharmaceutical Sci., 2(1/2):107-113 (1992).Applicant
• Hirano et al, “Pulmonary clearance and Toxicity of Zinc Oxide Instilled into the Rat Lung,” Toxicology 63:336-342 (1989).Applicant
• Illum, “Microspheres as a Potential Controlled Release Nasal Drug Delivery System,” Delivery Systems for Peptide Drugs, NY: Plenum, 1986.Applicant
• Johnson et al., “Delivery of Albuterol and Ipratropiumbromide from Two Nebulizer Systems in Chronic Stable Asthma,” Chest, 96, 6-10, 1989.Applicant
• Kassem and Ganderton, “The Influence of Carrier Surface on the Characteristics of Inspirable Powder Aerosols,” J. Pharm. Pharmacol., 42:11 (1990).Applicant
• Kawaguchi et al., “Phagocytosis of latex particles by leukocytes. I. Dependence of phagocytosis on the size and surface potential of particles,” Biomaterials 7: 61-66 (1986).Applicant
• Kobayashi et al., “Pulmonary Delivery of Salmon Calcitonin Dry Powders Containing Absorption Enhancers in Rats,” Pharm. Res., 13(1): 80-83 (1996).Applicant
• Komada et al., “Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung,” J. Pharm. Sci. 83(6):863-867 (Jun., 1994).Applicant
• Krenis and Strauss, “Effect of Size and Concentration of Latex Particles on Respiration of Human Blood Leucocytes,” Proc. Soc. Exp. Med., 107:748-750 (1961).Applicant
• Lai et al., “Sustained bronchodilation with isoproterenol poly(glycolide-co-lactide) microspheres,” Pharm. Res., 10(1) 119-125 (1993).Applicant
• Landahl, “On the removal of air-borne droplets by the human respiratory tract: I. The lung,” Bull. Math. Biophys., 12:43-56 (1950).Applicant
• Langer, “New Methods of Drug Delivery,” Science, 249:1527-1533 (1990).Applicant
• LeCorre et al., Preparation and characterization of bupivacaine-loaded polylactide and polylactide co-glycolide microspheres, Int. J. Pharmaceutics, 107:41-49 (1994).Applicant
• Leone-Bay et al., “Microsphere formation in a series of derivatized α-amino acids: Properties, molecular modeling and oral delivery of salmon calcitonin,” J. Med. Chem., 38:4257-4262 (1995).Applicant
• Liu et al., “Pulmonary Delivery of Free and Liposomal Insulin,” Pharm. Res. 10(2):228-232 (1993).Applicant
• Liu et al., “Moisture-induced aggregation of lyophilized proteins in the solid state,” Biotechnol. Bioeng., 37: 177-184 (1991).Applicant
• Martonen, “Mathematical model for the selective deposition of inhaled pharmaceuticals”, J. Pharm. Sci., 82(12):1191-1198 (1993).Applicant
• Masinde and Hickey, “Aerosolized aqueous suspensions of poly(L-lactic acid) microspheres,” Int. J. Pharmaceutics, 100:123-131 (1993).Applicant
• Mathiowitz et al., “Novel microcapsules for delivery systems,” Reactive Polymers 6, 275-283 (1987).Applicant
• Mathiowitz et al., “Polyanhydride microspheres. IV. Morphology and characterization of systems made by spray drying,” J. Appl. Polymer Sci. 45, 125-134 (1992).Applicant
• Mathiowitz et al., “Morphology of polyanhydride microsphere delivery systems,” Scanning Microscopy 4: 329-340 (1990).Applicant
• Mathiowitz and Langer, “Polyanhydride Microspheres as Drug Carriers I. Hot-Melt Microencapsulation,” J. Controlled Release 5,13-22 (1987).Applicant
• Mathiowitz et al., “Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal,” J. Appl. Polymer Sci. 35, 755-774 (1988).Applicant
• Moren, “Aerosol dosage forms and formulations,” in: Aerosols in Medicine. Principles, Diagnosis and Therapy, Moren, et al., Eds, Elsevier, Amsterdam, 1985.Applicant
• Morimoto and Adachi, “Pulmonary Uptake of Liposomal Phosphatidylcholine Upon Intratracheal Administration to Rats,” Chem. Pharm. Bull. 30(6):2248-2251 (1982).Applicant
• Mulligan, “The Basic Science of Gene Therapy,” Science, 260: 926-932 (1993).Applicant
• Mumenthaler et al., “Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator,” Pharm. Res., 11: 12-20 (1994).Applicant
• Niven et al., “The Pulmonary Absorption of Aerosolized and Intratracheally Instilled rhG-CSF and monoPEGylated rhG-CSF,” Pharm. Res., 12(9): 1343-1349 (1995).Applicant
• Okumura et al., “Intratracheal delivery of insulin. Absorption from solution and aerosol by rat lung,” Int. J. Pharmaceutics, 88:63-73 (1992).Applicant
• Patton and Platz, “(D) Routes of Delivery: Case Studies (2) Pulomonary delivery of peptides and proteins,” Adv. Drug Del. Rev., 8: 179-196 (1992).Applicant
• Patton et al., “Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones,” J. Controlled Release, 28: 79-85 (1994).Applicant
• **Pavia, “Lung Mucociliary Clearance,” in Aerosols and the Lung: Clinical and Experimental Aspects, Clarke, S.W. and Pavia, D., Eds., Butterworths, London, 1984.Applicant
• **Phalen, Inhalation Studies: Foundations and Techniques. CRC Press (Boca Raton, Fl), 1984.Applicant
• Pinkerton et al., “Aerosolized fluorescent microspheres detected in the lung using confocal scanning laser microscopy,” Microscopy Res. and Techn., 26:437-443 (1993).Applicant
• Rudt and Muller, “In vitro Phagocytosis Assay of Nano- and Microparticles by chemiluminescence. I. Effect of Analytical Parameters, Particle Size and Particle Concentration,” J. Contr. Rel., 22: 263-272 (1992).Applicant
• Rudt et al., “In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. IV. Effect of surface modification by coating of particles with poloxamine and Antarox CO on the phagocytic uptake,” J. Contr. Rel. 25:123 (1993).Applicant
• Ruffin et al., “The Preferential Deposition of Inhaled Isoproterenol and Propanolol in Asthmataic Patients,” Chest 80:904-907 (1986).Applicant
• Sela et al., “Multichain Polyamino Acids,” J. Am. Chem. Soc., 78:746 (1956).Applicant
• Swift, “The oral airway—a conduit or collector for pharmaceutical aerosols?” Respiratory Drug Delivery IV, 187:194 (1994).Applicant
• Tabata et al., “Controlled Delivery Systems for Proteins Using Polyanhydride Microspheres,” Pharm. Res., 10(4): 487-496 (1993).Applicant
• Tabata and Ikada, “Effect of surface wettability of microspheres on phagocytosis,” J. Colloid and Interface Sci., 127(1): 132-140 (1989).Applicant
• Tabata and Ikada, “Macrophage Phagocytosis of Biodegradable Microspheres Composed of L-lactic Acid/Glycolic Acid Homo- and Copolymers,” J. Biomed. Mater. Res., 22: 837-858 (1988).Applicant
• Tabata and Ikada, “Effect of size and surface charge of polymer microspheres on their phagocytosis by macrophage,” J. Biomed. Mater. Res., 22:837 (1988).Applicant
• Tansey, “The challenges in the development of metered dose inhalation aerosols using ozone-friendly propellants,” Spray Technol. Market, 4:26-29 (1994).Applicant
• Timsina et al., “Drug delivery to the respiratory tract using dry powder inhalers,” Int. J. Pharm., 101: 1-13 (1994).Applicant
• Turner, J. and S. Hering, “Greased and oiled substrates as bounce-free impaction surfaces,” J. Aerosol Sci., 18: 215-224 (1987).Applicant
• **Vincent, Aerosol Science for Industrial Hygientists, Pergamon Press, NY (1995).Applicant
• Visser, “An Invited Review: Van der Waals and Other Cohesive Forces Affecting Powder Fluidization,” Powder Technology 58: 1-10 (1989).Applicant
• Wall, “Pulmonary Absorption of Peptides and Proteins,” Drug Delivery, 2:1-20 (1995).Applicant
• Warheit and Hartsky, “Role of alveolar macrophage chemotaxis and phagocytosis in pulmonary clearance to inhaled particles: Comparisons among rodent species,” Microscopy Res. Tech., 26: 412-422 (1993).Applicant
• **Weibel, Morphometry of the Human Lung, New York: Academic Press (1963).Applicant
• Wong and Suslick, “Sonochemically produced hemoglobin microbubbles,” Mat. Res. Soc. Symp. Proc., 372:89-95 (1995).Applicant
• Zanen et al., “The optimal particle size for β-adrenergic aerosols in mild asthmatics,” Int. J. Pharm., 107: 211-217 (1994).Applicant
• Zanen et al., “The optimal particle size for parasympathicolytic aerosols in mild asthmatics” Int. J. Pharm., 114:111-115 (1995).Applicant
• Zeng et al., “The controlled delivery of drugs to the lung,” Int. J. Pharm., 124: 149-164 (1995).Applicant